Bayer, Wins

Bayer Wins Court Backing for $7.25 Billion Roundup Cap as Two Brokers Raise Their Targets

Published on 11/22/2026 at 11:31 | Editorial boerse-global.de
A Missouri court granted final approval to Bayer's US Roundup class settlement, capping Monsanto's payout at up to $7.25 billion over as many as 21 years.
Bayer, Wins, Court, Backing, Billion, Roundup, Cap, Two, Brokers, Raise Illustration mit AI erstellt.

Bayer's legal overhang has a ceiling now — at least on paper. A Missouri court granted final approval on Friday to the US class settlement covering Roundup claims tied to non-Hodgkin lymphoma, capping Monsanto's payout at up to $7.25 billion including sums already disbursed.

The structure spreads the burden across as many as 21 years, with annual payments that are capped and step down over time. Bayer framed the ruling as a milestone in its push to contain both pending and potential future litigation. There is a caveat attached: the approval can be appealed, and any appeal would suspend further payments until the appeals process runs its course.

Investors greeted the decision with a modest move in the regular session, lifting the stock 1.2% to €55.16 on the same trading day. In after-hours Tradegate trading immediately following the ruling, the shares had initially climbed 3%.

Should investors sell immediately? Or is it worth buying Bayer?

Two brokers, two targets, one direction

Analyst revisions have tracked the improving news flow. Kepler Cheuvreux raised its price target to €68 from €59 on Thursday while keeping its buy recommendation. Berenberg had moved the previous day, lifting its target to €62.00 from €53.50 but staying at "Hold." The private bank pointed to momentum in the pharmaceuticals division and to possible proceeds from a Monsanto IPO toward the end of the decade.

Deutsche Bank Research also lifted its target, to €65 from €60, on 10 November, reaffirming its buy call.

Guidance raised after a solid quarter

The operating picture behind those revisions came into focus with third-quarter 2026 results: group revenue of €10.1 billion and EBITDA before special items of €1.62 billion. Management raised its outlook for the pharma division's margin, for adjusted group EBITDA and for free cash flow.

On the product side, the US Food and Drug Administration approved Asundexian under the brand name Sunharbo. The drug is intended for certain adults, used alongside an antiplatelet agent, to lower the risk of further strokes. Bayer described it as the world's first approved factor XIa inhibitor.

Ad

Bayer Stock: New Analysis - 22 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYER | boerse | 70544135 |